Oral mosapride can provide additional anti-emetic efficacy following total joint arthroplasty under general anesthesia: a randomized, double-blinded clinical trial

Table 3 Timing of PONV events during the postoperative period

Time	Control (n = 80)	Dexa (n = 82)	Mosa+Dexa (n = 78)	p*	p1^†	p2^†	p3^†
Nausea	35 (43.8%)	16 (19.5%)	5 (6.4%)	< 0.001	0.001	< 0.001	0.014
0–6 h	30 (37.5%)	14 (17.1%)	5 (6.4%)	< 0.001	0.003	< 0.001	0.037
6–12 h	26 (32.5%)	13 (15.9%)	3 (3.8%)	< 0.001	0.002	< 0.013	0.011
12–24 h	8 (10%)	3 (3.7%)	0	0.006	0.109	0.007	0.246
24–48 h	6 (7.5%)	1 (1.2%)	0	0.013	0.062	0.028	1.000
Vomiting	9 (11.2%)	5 (6.1%)	3 (3.9%)	0.176
0–6 h	7 (23.8%)	4 (12.2%)	3 (3.8%)	0.380
6–12 h	3 (12.5%)	2 (6.1%)	1 (1.3%)	0.610
12–24 h	1 (1.3%)	1 (1.2%)	0	1.000
24–48 h	1 (1.3%)	0	0	0.652

Data presented as number of patients (percentage). Dexa, dexamethasone; Mosa, mosapride; PONV, postoperative nausea and vomiting
* Uncorrected values
^† Bonferroni-corrected p values: p1, Control vs Dexa; p2, Control vs. Mosa+Dexa; p3, Dexa vs. Mosa-Dexa. The corrected significance threshold was 0.016

ISSN: 1471-2253